Table 1.
Patient demographics and clincopathologic details for entire cohort and according to CTC-detectability
| Total (n=92) | CTC-Detectable (n=38) | CTC-Undetectable (n=54) | p-value | ||
|---|---|---|---|---|---|
| Gender | 0.37 | ||||
| Male | 39 (42%) | 14 (37%) | 25 (46%) | ||
| Female | 53 (58%) | 24 (63%) | 29 (54%) | ||
| Age | 0.52 | ||||
| Median (IQR) | 71 (66–78) | 71 (66–80) | 71 (65–78) | ||
| Range | 55–93 | 59–93 | 55–91 | ||
| Race | 0.53 | ||||
| White | 74 (80%) | 33 (87%) | 41 (76%) | ||
| African-American | 14 (15%) | 4 (10%) | 10 (19%) | ||
| Asian | 1 (1%) | 0 (0%) | 1 (2%) | ||
| Other | 3 (3%) | 1 (3%) | 2 (4%) | ||
| Body Mass Index | 0.62 | ||||
| Median (IQR) | 26 (23–31) | 27 (23–30) | 26 (23–31) | ||
| Range | 16–43 | 19–38 | 16–43 | ||
| Smoking Status | 0.85 | ||||
| Former | 69 (75%) | 29 (76%) | 40 (74%) | ||
| Current | 19 (20%) | 7 (18%) | 12 (22%) | ||
| Never | 4 (5%) | 2 (5%) | 2 (4%) | ||
| Pack-years | 0.90 | ||||
| Median (IQR) | 40 (25–68) | 40 (25–69) | 40 (25–60) | ||
| Range | 0–200 | 0–200 | 0–165 | ||
| Tumor Size (cm) | 0.03 | ||||
| Median (IQR) | 1.7 (1.2–2.2) | 1.4 (1.2–2.0) | 1.8 (1.2–2.4) | ||
| Range | 0.5–5 | 0.5–3.9 | 0.9–5.0 | ||
| Tumor SUV | 0.14 | ||||
| Median (IQR) | 4.3 (2.5–8.4) | 3.9 (2.2–7.8) | 4.8 (2.5–9.9) | ||
| Range | 0.8–19.9 | 0.8–13.3 | 0.8–19.9 | ||
| AJCC Stage | 0.69 | ||||
| IA | 81 (88%) | 34 (89%) | 47 (87%) | ||
| IB | 11 (12%) | 4 (11%) | 7 (13%) | ||
| T Stage | 0.11 | ||||
| 1a | 59 (64%) | 29 (76%) | 30 (56%) | ||
| 1b | 21 (23%) | 5 (13%) | 16 (30%) | ||
| 2a | 12 (13%) | 4 (10%) | 8 (15%) | ||
| Histology | 0.22 | ||||
| Adenocarcinoma | 22 (24%) | 7 (18%) | 15 (28%) | ||
| Squamous cell | 15 (16%) | 9 (24%) | 6 (11%) | ||
| Not pathologically confirmed | 55 (60%) | 22 (58%) | 33 (61%) | ||
| Previous NSCLC | <0.01 | ||||
| Yes | 17 (19%) | 12 (32%) | 5 (9%) | ||
| No | 75 (81%) | 26 (68%) | 49 (91%) | ||